To know the exact growth variance and the Y-O-Y growth rate - Request a free sample report.
Central Nervous System (CNS) Stimulant Drugs Market 2022-2026: Scope
Our central nervous system (CNS) stimulant drugs market report covers the following areas:
Central Nervous System (CNS) Stimulant Drugs Market 2022-2026: Drivers & Challenges
The key factor driving the central nervous system (CNS) stimulant drugs market growth is the rise in CNS disorders such as sleep apnea, narcolepsy, and attention-deficit hyperactivity disorder worldwide. As per Le et al. 2013, the global prevalence of attention-deficit hyperactivity disorder in children and adolescents was estimated to be 5.3%-5.9%, while in Europe, 4.6% of children and adolescents were estimated to have attention-deficit hyperactivity disorder. According to the CDC, in the US, 5% of children have attention-deficit hyperactivity disorder. In 2016, an estimated 6.1 million children were diagnosed with attention-deficit hyperactivity disorder in the US.
However, the key challenges to the global central nervous system (CNS) stimulant drugs market growth are the numerous side effects of drugs. For instance, the medication for attention-deficit hyperactivity disorder is effective in reducing the symptoms of the disease. However, the medication is also associated with side effects. Medications such as methylphenidates, including RITALIN, Focalin, Metadate, and CONCERTA, whereas amphetamines such as DEXEDRINE, Adderall, and VYVANSE have some potential side effects such as sleep problems, reduced appetite, increased blood pressure, headaches, stomach ache, nervousness, and moodiness, and irritability. Furthermore, amphetamines have been used to improve alertness in narcolepsy. These medications are the most effective in reducing sleepiness.
To know about more drivers & challenges - Download a free sample now!
Central Nervous System (CNS) Stimulant Drugs Market 2022-2026: Segmentation
- Application
- Attention-deficit Hyperactivity Disorder
- Narcolepsy
- Others
- Geography
- North America
- Europe
- Asia
- Rest Of World (ROW)
Central Nervous System (CNS) Stimulant Drugs Market 2022-2026: Revenue Generating Segment & Regional Analysis
- The central nervous system (CNS) stimulant drugs market share growth by the attention-deficit hyperactivity disorder segment will be significant for revenue generation. The growth is attributed to the significant increase in the prevalence of attention-deficit hyperactivity disorder in both adolescents and children. In addition, the easy availability of stimulants to treat attention-deficit hyperactivity disorder will accelerate market growth during the forecast period.
- 46% of the market's growth will originate from North America during the forecast period. US, Canada, and Mexico are the key markets for the central nervous system (CNS) stimulant drugs in North America. Market growth in this region will be faster than the growth of the market in Europe. The significant increase in the prevalence of CNS disorders, such as autism and attention-deficit hyperactivity disorder will facilitate the central nervous system (CNS) stimulant drugs market growth in North America over the forecast period.
For more insights on the market share of various segments - Download a free sample now!
Central Nervous System (CNS) Stimulant Drugs Market 2022-2026: Key Highlights
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist central nervous system (CNS) stimulant drugs market growth during the next five years
- Estimation of the central nervous system (CNS) stimulant drugs market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the central nervous system (CNS) stimulant drugs market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of central nervous system (CNS) stimulant drugs market vendors
Subscribe to our "Lite Plan" billed annually at USD 3000 that enables you to download 3 reports/year and view 3 reports/month.
Related Reports:
- The pruritus drugs market share is expected to increase by USD 6.87 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.06%. Download a free sample now!
- The new drug delivery systems market share is expected to increase by USD 77.29 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.08%. Download a free sample now!
Central Nervous System (CNS) Stimulant Drugs Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.74% |
Market growth 2022-2026 |
USD 5.95 billion |
Market structure |
Fragmented |
YoY growth (%) |
5.52 |
Performing market contribution |
North America at 46% |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Astellas Pharma Inc., Biogen Inc., Endo International Plc, GlaxoSmithKline Plc, Highland Therapeutics Inc., Jazz Pharmaceuticals Plc, Johnson and Johnson Inc., KemPharm Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue Pharma LP, Sanofi SA, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Tris Pharma Inc., UCB SA, and Viatris Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period, |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table Of Contents :
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Application
- 5.1 Market segments
- Exhibit 24: Chart on Application - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Application - Market share 2021-2026 (%)
- 5.2 Comparison by Application
- Exhibit 26: Chart on Comparison by Application
- Exhibit 27: Data Table on Comparison by Application
- 5.3 Attention-deficit hyperactivity disorder - Market size and forecast 2021-2026
- Exhibit 28: Chart on Attention-deficit hyperactivity disorder - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Attention-deficit hyperactivity disorder - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Attention-deficit hyperactivity disorder - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Attention-deficit hyperactivity disorder - Year-over-year growth 2021-2026 (%)
- 5.4 Narcolepsy - Market size and forecast 2021-2026
- Exhibit 32: Chart on Narcolepsy - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Narcolepsy - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Narcolepsy - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Narcolepsy - Year-over-year growth 2021-2026 (%)
- 5.5 Others - Market size and forecast 2021-2026
- Exhibit 36: Chart on Others - Market size and forecast 2021-2026 ($ million)
- Exhibit 37: Data Table on Others - Market size and forecast 2021-2026 ($ million)
- Exhibit 38: Chart on Others - Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Others - Year-over-year growth 2021-2026 (%)
- 5.6 Market opportunity by Application
- Exhibit 40: Market opportunity by Application ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 42: Chart on Market share by geography 2021-2026 (%)
- Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 44: Chart on Geographic comparison
- Exhibit 45: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Canada - Market size and forecast 2021-2026
- Exhibit 66: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.9 UK - Market size and forecast 2021-2026
- Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10 Germany - Market size and forecast 2021-2026
- Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.11 China - Market size and forecast 2021-2026
- Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.12 Mexico - Market size and forecast 2021-2026
- Exhibit 82: Chart on Mexico - Market size and forecast 2021-2026 ($ million)
- Exhibit 83: Data Table on Mexico - Market size and forecast 2021-2026 ($ million)
- Exhibit 84: Chart on Mexico - Year-over-year growth 2021-2026 (%)
- Exhibit 85: Data Table on Mexico - Year-over-year growth 2021-2026 (%)
- 7.13 Market opportunity by geography
- Exhibit 86: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.3 Impact of drivers and challenges
- Exhibit 87: Impact of drivers and challenges in 2021 and 2026
9 Vendor Landscape
- 9.2 Vendor landscape
- Exhibit 88: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 89: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 90: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 91: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 92: Matrix on vendor position and classification
- 10.3 Biogen Inc.
- Exhibit 93: Biogen Inc. - Overview
- Exhibit 94: Biogen Inc. - Product / Service
- Exhibit 95: Biogen Inc. - Key offerings
- 10.4 Endo International Plc
- Exhibit 96: Endo International Plc - Overview
- Exhibit 97: Endo International Plc - Business segments
- Exhibit 98: Endo International Plc - Key news
- Exhibit 99: Endo International Plc - Key offerings
- Exhibit 100: Endo International Plc - Segment focus
- 10.5 GlaxoSmithKline Plc
- Exhibit 101: GlaxoSmithKline Plc - Overview
- Exhibit 102: GlaxoSmithKline Plc - Business segments
- Exhibit 103: GlaxoSmithKline Plc - Key news
- Exhibit 104: GlaxoSmithKline Plc - Key offerings
- Exhibit 105: GlaxoSmithKline Plc - Segment focus
- 10.6 Johnson and Johnson Inc.
- Exhibit 106: Johnson and Johnson Inc. - Overview
- Exhibit 107: Johnson and Johnson Inc. - Business segments
- Exhibit 108: Johnson and Johnson Inc. - Key news
- Exhibit 109: Johnson and Johnson Inc. - Key offerings
- Exhibit 110: Johnson and Johnson Inc. - Segment focus
- 10.7 Merck and Co. Inc.
- Exhibit 111: Merck and Co. Inc. - Overview
- Exhibit 112: Merck and Co. Inc. - Business segments
- Exhibit 113: Merck and Co. Inc. - Key news
- Exhibit 114: Merck and Co. Inc. - Key offerings
- Exhibit 115: Merck and Co. Inc. - Segment focus
- 10.8 Novartis AG
- Exhibit 116: Novartis AG - Overview
- Exhibit 117: Novartis AG - Business segments
- Exhibit 118: Novartis AG - Key offerings
- Exhibit 119: Novartis AG - Segment focus
- 10.9 Pfizer Inc.
- Exhibit 120: Pfizer Inc. - Overview
- Exhibit 121: Pfizer Inc. - Product / Service
- Exhibit 122: Pfizer Inc. - Key news
- Exhibit 123: Pfizer Inc. - Key offerings
- 10.10 Sanofi SA
- Exhibit 124: Sanofi SA - Overview
- Exhibit 125: Sanofi SA - Business segments
- Exhibit 126: Sanofi SA - Key news
- Exhibit 127: Sanofi SA - Key offerings
- Exhibit 128: Sanofi SA - Segment focus
- 10.11 Takeda Pharmaceutical Co. Ltd.
- Exhibit 129: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 130: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 131: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 132: Takeda Pharmaceutical Co. Ltd. - Key offerings
- 10.12 Teva Pharmaceutical Industries Ltd.
- Exhibit 133: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 134: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 135: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 136: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 137: Teva Pharmaceutical Industries Ltd. - Segment focus
11 Appendix
- 11.2 Inclusions and exclusions checklist
- Exhibit 138: Inclusions checklist
- Exhibit 139: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 140: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 141: Research methodology
- Exhibit 142: Validation techniques employed for market sizing
- Exhibit 143: Information sources
- 11.5 List of abbreviations
- Exhibit 144: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article